Orlov S. Nicole Schaeffer - 01 Nov 2021 Form 4 Insider Report for INSMED Inc (INSM)

Role: Chief People Strategy Officer
Signature: /s/ S. Nicole Schaeffer
Issuer symbol: INSM
Transactions as of: 01 Nov 2021
Net transactions value: -$1,088,512
Form type: 4
Filing time: 03 Nov 2021, 16:27:59 UTC
Previous filing: 18 May 2021
Next filing: 07 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INSM	Common Stock	Options Exercise	$758,840	+61,000	+118%	$12.44	112,514	01 Nov 2021	Direct	F1, F2
transaction	INSM	Common Stock	Sale	$1,836,785	-60,660	-54%	$30.28	51,854	01 Nov 2021	Direct	F1, F3
transaction	INSM	Common Stock	Sale	$10,567	-340	-0.66%	$31.08	51,514	01 Nov 2021	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INSM	Stock Option (right to buy)	Options Exercise	$0	-36,000	-59%	$0.000000	25,000	01 Nov 2021	Common Stock	36,000	$12.44	Direct	F5
transaction	INSM	Stock Option (right to buy)	Options Exercise	$0	-25,000	-100%	$0.000000^*	0	01 Nov 2021	Common Stock	25,000	$12.44	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2	Includes 722 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
F3	This is the weighted average sales price representing 60,660 shares sold at prices ranging from $30.00 to $30.99 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4	This is the weighted average sales price representing 340 shares sold at prices ranging from $31.00 to $31.14 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F5	The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
F6	These options vested and became exercisable with respect to 12,500 shares upon receipt of the first written acceptance of an NDA or MAA filing from an applicable regulatory authority (FDA or EMA); and with respect to the remaining 12,500 shares upon receipt of the first written approval of an NDA or MAA filing from an applicable regulatory authority (FDA or EMA).